Advertisement
AMLX vs CRBP
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMLX is a StrongBuy and CRBP is a StrongBuy.
Momentum Indicator for AMLX turns positive, indicating new upward trend
AMLX saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 79 similar instances where the indicator turned positive. In 70 of the 79 cases, the stock moved higher in the following days. The odds of a move higher are at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AMLX's RSI Indicator exited the oversold zone, 25 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for AMLX just turned positive on October 20, 2026. Looking at past instances where AMLX's MACD turned positive, the stock continued to rise in 34 of 42 cases over the following month. The odds of a continued upward trend are 81%.
Following a +6.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMLX advanced for three days, in 233 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
AMLX moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for AMLX crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMLX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
AMLX broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for AMLX entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. AMLX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.235) is normal, around the industry mean (11.138). P/E Ratio (-20.589) is within average values for comparable stocks, (-7.600). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (3.627) is also within normal values, averaging (178.797).
The Tickeron Profit vs. Risk Rating rating for this company is 70 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AMLX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
CRBP's Stochastic Oscillator sits in oversold zone for 16 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 18 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
Following a +5.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRBP advanced for three days, in 227 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The 50-day moving average for CRBP moved below the 200-day moving average on October 07, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRBP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for CRBP entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.811) is normal, around the industry mean (2.988). P/E Ratio (-0.701) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. CRBP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRBP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
CRBP | ||
|---|---|---|
OUTLOOK RATING 1..100 | 51 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 64 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 98 | |
PRICE GROWTH RATING 1..100 | 93 | |
P/E GROWTH RATING 1..100 | 9 | |
SEASONALITY SCORE 1..100 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| AMLX | CRBP | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 83% | 1 day ago 79% |
| Stochastic ODDS (%) | 1 day ago 82% | 1 day ago 88% |
| Momentum ODDS (%) | 1 day ago 89% | N/A |
| MACD ODDS (%) | 1 day ago 81% | N/A |
| TrendWeek ODDS (%) | 1 day ago 82% | 1 day ago 88% |
| TrendMonth ODDS (%) | 1 day ago 88% | 1 day ago 88% |
| Advances ODDS (%) | 1 day ago 80% | about 1 month ago 82% |
| Declines ODDS (%) | 10 days ago 80% | 1 day ago 87% |
| BollingerBands ODDS (%) | 1 day ago 77% | N/A |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMLX’s FA Score shows that 0 FA rating(s) are green while CRBP’s FA Score has 1 green FA rating(s).
- AMLX’s FA Score: 0 green, 5 red.
- CRBP’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMLX’s TA Score shows that 4 TA indicator(s) are bullish while CRBP’s TA Score has 3 bullish TA indicator(s).
- AMLX’s TA Score: 4 bullish, 6 bearish.
- CRBP’s TA Score: 3 bullish, 3 bearish.
Price Growth
AMLX (@Pharmaceuticals: Generic) experienced а +7.40% price change this week, while CRBP (@Biotechnology) price change was -2.83% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.91%. For the same industry, the average monthly price growth was -7.64%, and the average quarterly price growth was +9.46%.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.90%. For the same industry, the average monthly price growth was -15.91%, and the average quarterly price growth was -14.30%.
Reported Earning Dates
AMLX is expected to report earnings on Nov 05, 2026.
CRBP is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-0.91% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
@Biotechnology (+1.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
AMLX and
Correlation & Price change
A.I.dvisor indicates that over the last year, AMLX has been loosely correlated with OCUL. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if AMLX jumps, then OCUL could also see price increases.
| Ticker / NAME | Correlation To AMLX | 1D Price Change % | ||
|---|---|---|---|---|
| AMLX | 100% | +0.90% | ||
| OCUL - AMLX | 46% Loosely correlated | -2.56% | ||
| LRMR - AMLX | 45% Loosely correlated | -0.82% | ||
| JAZZ - AMLX | 43% Loosely correlated | -0.84% | ||
| RGNX - AMLX | 43% Loosely correlated | -3.11% | ||
| IDYA - AMLX | 43% Loosely correlated | +0.31% | ||
More | ||||
CRBP and
Correlation & Price change
A.I.dvisor indicates that over the last year, CRBP has been loosely correlated with KURA. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if CRBP jumps, then KURA could also see price increases.
| Ticker / NAME | Correlation To CRBP | 1D Price Change % | ||
|---|---|---|---|---|
| CRBP | 100% | -3.05% | ||
| KURA - CRBP | 38% Loosely correlated | -1.00% | ||
| BCYC - CRBP | 37% Loosely correlated | -0.83% | ||
| AMLX - CRBP | 37% Loosely correlated | +0.90% | ||
| CCCC - CRBP | 36% Loosely correlated | +0.32% | ||
| RNAC - CRBP | 36% Loosely correlated | +0.39% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SOR | 45.70 | 0.55 | +1.22% |
| Source Capital | |||
| GLDN | 15.16 | 0.08 | +0.54% |
| Nicholas Gold Income ETF (GLDN) | |||
| ITDD | 38.60 | 0.12 | +0.31% |
| iShares LifePath Target Date 2040 ETF (ITDD) | |||
| TIPX | 18.39 | 0.01 | +0.05% |
| State Street SPDR Bloomberg 1-10 Year TIPS ETF (TIPX) | |||
| AZTD | 31.30 | N/A | N/A |
| Aztlan Global Stock Selection DM SMID ETF (AZTD) | |||